HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korean Health Ministry’s Bill To Allow OTC Sales In Supermarkets Seen Stalled At National Assembly

This article was originally published in PharmAsia News

Executive Summary

The Health Ministry’s bill to allow sales of some OTC products in supermarkets looks to be doomed as lawmakers prepare for upcoming elections.

You may also be interested in...



Korea's Pharmacists, Doctors Clash Over Prescription Drug Sales; Ministry Calls For Expanded Painkiller Distribution

SEOUL - What started as a simple task of widening public access to some over-the-counter drugs has now evolved into a turf war between South Korea's pharmacist and doctor associations, and the Ministry of Health And Welfare is now calling for a new round of OTC distribution revisions before the first round has finished

Korea's Health Ministry Flip-Flops Again On OTC Drug Position; Now Seeks Expanded Consumer Access

SEOUL - Just a few days after South Korea's Ministry of Health and Welfare announced it would not allow sales of OTC drugs at supermarkets and convenience stores, the ministry is reversing its position, saying it will now push for a revision of Korea's drug law to allow sales of OTC products in the stores

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS139001

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel